Naoxintong capsule delay the progression of diabetic kidney disease: A real-world cohort study
Open Access
- 3 November 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1037564
Abstract
Introduction: Diabetic kidney disease (DKD) is a severe and growing health problem, associated with a worse prognosis and higher overall mortality rates than non-diabetic renal disease. Chinese herbs possess promising clinical benefits in alleviating the progression of DKD due to their multi-target effect. This real-world retrospective cohort trial aimed to investigate the efficacy and safety of Naoxintong (NXT) capsules in the treatment of DKD. Our study is the first real-world study (RWS) of NXT in the treatment of DKD based on a large database, providing a basis for clinical application and promotion.Methods: The data was collected from Tianjin Healthcare and Medical Big Data Platform. Patients with DKD were enrolled from January 1, 2011, to March 31, 2021. NXT administration was defined as the exposure. The primary outcome was the change in estimated glomerular filtration rate (eGFR). We employed the propensity score matching (PSM) method to deal with confounding factors.Results: A total of 1,798 patients were enrolled after PSM, including 899 NXT users (exposed group) and 899 non-users (control group). The eGFR changes from baseline to the end of the study were significantly different in the exposed group compared to the control group (-1.46 ± 21.94 vs -5.82 ± 19.8 mL/(min·1.73m2), P< 0.01). Patients in the NXT group had a lower risk of composite renal outcome event (HR, 0.71; 95%CI, 0.55 to 0.92; P = 0.009) and deterioration of renal function (HR, 0.74; 95% CI, 0.56 to 0.99; P = 0.039).Conclusion: NXT can significantly slow the decline of eGFR and reduce the risk of renal outcomes. However, large cohort studies and RCTs are needed to further confirm our results.Keywords
This publication has 40 references indexed in Scilit:
- Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesKidney International, 2015
- Have we reached the limits for the treatment of diabetic nephropathy?Expert Opinion on Investigational Drugs, 2014
- Stratified Fisher's exact test and its sample size calculationBiometrical Journal, 2013
- Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid conditionDiabetologia, 2013
- Amygdalin inhibits renal fibrosis in chronic kidney diseaseMolecular Medicine Reports, 2013
- One‐to‐many propensity score matching in cohort studiesPharmacoepidemiology and Drug Safety, 2012
- Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?Nephron Clinical Practice, 2011
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetesExperimental & Molecular Medicine, 2011
- Trends in Alternative Medicine Use in the United States, 1990-1997JAMA, 1998